207 related articles for article (PubMed ID: 28929345)
1. Pemafibrate: First Global Approval.
Blair HA
Drugs; 2017 Oct; 77(16):1805-1810. PubMed ID: 28929345
[TBL] [Abstract][Full Text] [Related]
2. The novel selective PPARα modulator (SPPARMα) pemafibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis.
Hennuyer N; Duplan I; Paquet C; Vanhoutte J; Woitrain E; Touche V; Colin S; Vallez E; Lestavel S; Lefebvre P; Staels B
Atherosclerosis; 2016 Jun; 249():200-8. PubMed ID: 27108950
[TBL] [Abstract][Full Text] [Related]
3. Effects of pemafibrate (K-877) on cholesterol efflux capacity and postprandial hyperlipidemia in patients with atherogenic dyslipidemia.
Yamashita S; Arai H; Yokote K; Araki E; Suganami H; Ishibashi S;
J Clin Lipidol; 2018; 12(5):1267-1279.e4. PubMed ID: 30077640
[TBL] [Abstract][Full Text] [Related]
4. Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases.
Yamashita S; Masuda D; Matsuzawa Y
Curr Atheroscler Rep; 2020 Jan; 22(1):5. PubMed ID: 31974794
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα): Pooled Analysis of Phase 2 and 3 Studies in Dyslipidemic Patients with or without Statin Combination.
Yamashita S; Arai H; Yokote K; Araki E; Matsushita M; Nojima T; Suganami H; Ishibashi S
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31698825
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-α Modulator (SPPARMα), in Dyslipidemic Patients with Renal Impairment.
Yokote K; Yamashita S; Arai H; Araki E; Suganami H; Ishibashi S; Of The K-Study Group OB
Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30736366
[TBL] [Abstract][Full Text] [Related]
7. Gene Expression Profiles Induced by a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα) Pemafibrate.
Sasaki Y; Raza-Iqbal S; Tanaka T; Murakami K; Anai M; Osawa T; Matsumura Y; Sakai J; Kodama T
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31766193
[TBL] [Abstract][Full Text] [Related]
8. Combination therapy with pemafibrate (K-877) and pitavastatin improves vascular endothelial dysfunction in dahl/salt-sensitive rats fed a high-salt and high-fat diet.
Yoshida M; Nakamura K; Miyoshi T; Yoshida M; Kondo M; Akazawa K; Kimura T; Ohtsuka H; Ohno Y; Miura D; Ito H
Cardiovasc Diabetol; 2020 Sep; 19(1):149. PubMed ID: 32979918
[TBL] [Abstract][Full Text] [Related]
9. Effect of pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor α modular (SPPARMα), in atherosclerosis model using low density lipoprotein receptor knock-out swine with balloon injury.
Konishi H; Miyauchi K; Onishi A; Suzuki S; Fuchimoto D; Shitara J; Endo H; Wada H; Doi S; Naito R; Ogita M; Dohi T; Kasai T; Daida H
PLoS One; 2020; 15(11):e0241195. PubMed ID: 33201888
[TBL] [Abstract][Full Text] [Related]
10. Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis.
Honda Y; Kessoku T; Ogawa Y; Tomeno W; Imajo K; Fujita K; Yoneda M; Takizawa T; Saito S; Nagashima Y; Nakajima A
Sci Rep; 2017 Feb; 7():42477. PubMed ID: 28195199
[TBL] [Abstract][Full Text] [Related]
11. Molecular association model of PPARα and its new specific and efficient ligand, pemafibrate: Structural basis for SPPARMα.
Yamamoto Y; Takei K; Arulmozhiraja S; Sladek V; Matsuo N; Han SI; Matsuzaka T; Sekiya M; Tokiwa T; Shoji M; Shigeta Y; Nakagawa Y; Tokiwa H; Shimano H
Biochem Biophys Res Commun; 2018 May; 499(2):239-245. PubMed ID: 29567478
[TBL] [Abstract][Full Text] [Related]
12. The Peroxisome Proliferator-Activated Receptor α (PPARα) Agonist Pemafibrate Protects against Diet-Induced Obesity in Mice.
Araki M; Nakagawa Y; Oishi A; Han SI; Wang Y; Kumagai K; Ohno H; Mizunoe Y; Iwasaki H; Sekiya M; Matsuzaka T; Shimano H
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30041488
[TBL] [Abstract][Full Text] [Related]
13. Selective Peroxisome Proliferator-Activated Receptor Alpha Modulators (SPPARMα): New Opportunities to Reduce Residual Cardiovascular Risk in Chronic Kidney Disease?
Fruchart JC; Hermans MP; Fruchart-Najib J
Curr Atheroscler Rep; 2020 Jul; 22(8):43. PubMed ID: 32671476
[TBL] [Abstract][Full Text] [Related]
14. Effects of K-877, a novel selective PPARα modulator, on small intestine contribute to the amelioration of hyperlipidemia in low-density lipoprotein receptor knockout mice.
Takei K; Nakagawa Y; Wang Y; Han SI; Satoh A; Sekiya M; Matsuzaka T; Shimano H
J Pharmacol Sci; 2017 Apr; 133(4):214-222. PubMed ID: 28366492
[TBL] [Abstract][Full Text] [Related]
15. Effect of pemafibrate, a novel selective peroxisome proliferator-activated receptor-alpha modulator (SPPARMα), on urinary protein excretion in IgA nephropathy with hypertriglyceridemia.
Tanaka A; Nakamura T; Sato E; Chihara A; Node K
CEN Case Rep; 2020 May; 9(2):141-146. PubMed ID: 31950425
[TBL] [Abstract][Full Text] [Related]
16. Clinical Applications of a Novel Selective PPARα Modulator, Pemafibrate, in Dyslipidemia and Metabolic Diseases.
Yamashita S; Masuda D; Matsuzawa Y
J Atheroscler Thromb; 2019 May; 26(5):389-402. PubMed ID: 30930344
[TBL] [Abstract][Full Text] [Related]
17. Pemafibrate, A Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator, Reduces Plasma Eicosanoid Levels and Ameliorates Endothelial Dysfunction in Diabetic Mice.
Suto K; Fukuda D; Shinohara M; Ganbaatar B; Yagi S; Kusunose K; Yamada H; Soeki T; Hirata KI; Sata M
J Atheroscler Thromb; 2021 Dec; 28(12):1349-1360. PubMed ID: 33775978
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of pemafibrate administration in patients with dyslipidemia: a systematic review and meta-analysis.
Ida S; Kaneko R; Murata K
Cardiovasc Diabetol; 2019 Mar; 18(1):38. PubMed ID: 30898163
[TBL] [Abstract][Full Text] [Related]
19. Elucidation of Molecular Mechanism of a Selective PPARα Modulator, Pemafibrate, through Combinational Approaches of X-ray Crystallography, Thermodynamic Analysis, and First-Principle Calculations.
Kawasaki M; Kambe A; Yamamoto Y; Arulmozhiraja S; Ito S; Nakagawa Y; Tokiwa H; Nakano S; Shimano H
Int J Mol Sci; 2020 Jan; 21(1):. PubMed ID: 31935812
[TBL] [Abstract][Full Text] [Related]
20. Marked effects of novel selective peroxisome proliferator-activated receptor α modulator, pemafibrate in severe hypertriglyceridemia: preliminary report.
Iitake C; Masuda D; Koseki M; Yamashita S
Cardiovasc Diabetol; 2020 Nov; 19(1):201. PubMed ID: 33246467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]